GIP contributes to islet trihormonal abnormalities in type 2 diabetes

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 7, 2014, Pages 2477-2485

  Chia, Chee W ^a   Odetunde, Juliana O ^a   Kim, Wook ^b   Carlson, Olga D ^a   Ferrucci, Luigi ^a   Egan, Josephine M ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b Ajou University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; METFORMIN; PANCREAS POLYPEPTIDE; PLACEBO; SULFONYLUREA;

AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DIABETES ASSOCIATED MULTIISLET HORMONE DYSREGULATION; DIABETES MELLITUS; DIET THERAPY; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; HORMONE RELEASE; HUMAN; HUMAN CELL; IMPAIRED GLUCOSE TOLERANCE; IN VITRO STUDY; INSULIN BLOOD LEVEL; INTERVENTION STUDY; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; UPREGULATION;

ADULT; AGED; ANIMALS; CASE-CONTROL STUDIES; CELLS, CULTURED; DIABETES MELLITUS, TYPE 2; FEMALE; GASTRIC INHIBITORY POLYPEPTIDE; HUMANS; ISLETS OF LANGERHANS; LONGITUDINAL STUDIES; MALE; MICE; MICE, INBRED C57BL; MIDDLE AGED; PANCREATIC DISEASES; PANCREATIC HORMONES;

EID: 84904060080     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-3994     Document Type: Article

References (30)

1. Unger RH, Orci L. The essential role of glucagon in the pathogenesis of diabetes mellitus. Lancet. 1975;1(7897):14-16.
2. Floyd JC Jr, Fajans SS, Pek S, Chance RE. A newly recognized pancreatic polypeptide; plasma levels in health and disease. Rec Prog Horm Res. 1976;33:519-570. (Pubitemid 8188773)
3. Reaven GM, Chen YD, Golay A, Swislocki AL, Jaspan JB. Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1987;64(1):106-110. (Pubitemid 17015886)
4. Chia CW, Carlson OD, Kim W, et al. Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes. Diabetes. 2009;58(6):1342-1349.
5. Gromada J, Franklin I, Wollheim CB. α-Cells of the endocrine pancreas: 35 years of research but the enigma remains. Endocr Rev. 2007;28(1):84-116. (Pubitemid 46220851)
6. Adrian TE, Besterman HS, Cooke TJ, Bloom SR, Barnes AJ, Russell RC. Mechanism of pancreatic polypeptide release in man. Lancet. 1977;1(8004):161- 163. (Pubitemid 8020485)
7. Meier JJ, Nauck MA. Glucagon-like peptide 1(GLP-1) in biology and pathology. Diabetes Metab Res Rev. 2005;21(2):91-117. (Pubitemid 40467658)
8. Meier JJ, Nauck MA. Clinical endocrinology and metabolism. Glucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptide. Best Pract Res Clin Endocrinol Metab. 2004;18(4):587-606. (Pubitemid 39481234)
9. Ryan AS, Egan JM, Habener JF, Elahi D. Insulinotropic hormone glucagon-like peptide-1-(7-37) appears not to augment insulin-mediated glucose uptake in young men during euglycemia. J Clin Endocrinol Metab. 1998;83(7):2399-2404. (Pubitemid 28503037)
10. Meier JJ, Kemmeries G, Holst JJ, Nauck MA. Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects. Diabetes. 2005;54(7):2212-2218. (Pubitemid 40911286)
11. Egan JM, Clocquet AR, Elahi D. The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes. J Clin Endocrinol Metab. 2002;87(3):1282-1290. (Pubitemid 36121100)
12. Egan JM, Meneilly GS, Elahi D. Effects of 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetes. Am J Physiol Endocrinol Metab. 2003;284(6):E1072-E1079. (Pubitemid 36617451)
13. Sive AA, Vinik AI, van Tonder SV. Pancreatic polypeptide (PP) responses to oral and intravenous glucose in man. Am J Gastroenterol. 1979;71(2):183-185. (Pubitemid 9140100)
14. Amland PF, Jorde R, Aanderud S, Burhol PG, Giercksky KE. Effects of intravenously infused porcine GIP on serum insulin, plasma Cpeptide, and pancreatic polypeptide in non-insulin-dependent diabetes in the fasting state. Scand J Gastroenterol. 1985;20(3):315-320. (Pubitemid 15089048)
15. Jorde R, Burhol PG. Release of plasma pancreatic polypeptide in achlorhydric patients after intravenous infusion of gastric inhibitory polypeptide. Digestion. 1983;27(4):239-244. (Pubitemid 14226078)
16. Brunicardi FC, Druck P, Sun YS, Elahi D, Gingerich RL, Andersen DK. Regulation of pancreatic polypeptide secretion in the isolated perfused human pancreas. Am J Surg. 1988;155(1):63-69. (Pubitemid 18063526)
17. Shock NW, Greulich RC, Andres RA, Arenberg D, Costa PT, Lakatta EG, Tobin JD. Normal Human Aging: The Baltimore Longitudinal Study of Aging. Washington, DC: US Government Printing Office; 1984.
18. Cabrera O, Berman DM, Kenyon NS, Ricordi C, Berggren P-O, Caicedo A. The unique cytoarchitecture of human pancreatic islets has implications for islet cell function. Proc Natl Acad Sci USA. 2006:103:2334-2339. (Pubitemid 43271670)
19. Magnusson I, Rothman DL, Katz LD, Shulman RG, Shulman GI. Increased rate of gluconeogenesis in type II diabetes mellitus. A 13C nuclear magnetic resonance study. J Clin Invest. 1992;90(4):1323-1327.
20. Magnusson I, Rothman DL, Gerard DP, Katz LD, Shulman GI. Contribution of hepatic glycogenolysis to glucose production in humans in response to a physiological increase in plasma glucagon concentration. Diabetes. 1995;44:185-189.
21. Hundal RS, Krssak M, Dufour S, et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes. 2000;49:2063-2069.
22. Lewis JT, Dayanandan B, Habener JF, Kieffer TJ. Glucose-dependent insulinotropic polypeptide confers early phase insulin release to oral glucose in rats: demonstration by a receptor antagonist. Endocrinology. 2000;141(10):3710-3716.
23. Moens K, Heimberg H, Flamez D, et al. Expression and functional activity of glucagon, glucagon-like peptide I, and glucose-dependent insulinotropic peptide receptors in rat pancreatic islet cells. Diabetes. 1996;45(2):257-261. (Pubitemid 26048675)
24. Brunicardi FC, Chaiken RL, Ryan AS, et al. Pancreatic polypeptide administration improves abnormal glucose metabolism in patients with chronic pancreatitis. J Clin Endocrinol Metab. 1996;81(10):3566-3572. (Pubitemid 26339916)
25. Nannipieri M, Baldi S, Mari A, et al. Roux-en-Y gastric bypass and sleeve gastrectomy: mechanisms of diabetes remission and role of gut hormones. J Clin Endocrinol Metab. 2013;98(11):4391-4399.
26. Theodorakis MJ, Carlson O, Michopoulos S, et al. Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP. Am J Physiol Endocrinol Metab. 2006;290(3):E550-E559. (Pubitemid 43671703)
27. Elahi D, McAloon-Dyke M, Fukagawa NK, et al. The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. Regul Pept. 1994;51(1):63-74. (Pubitemid 24119981)
28. Piteau S, Olver A, Kim S-J, et al. Reversal of islet GIP receptor down-regulation and resistance to GIP by reducing hyperglycemia in the Zucker rat. Biochem Biophys Res Commun. 2007;362(4):1007-1012. (Pubitemid 47398873)
29. Kennedy FP, Bolli GB, Go VLW, Cryer PE, Gericvh JE. The significance of impaired pancreatic polypeptide and epinephrine responses to hypoglycemia in patients with insulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1987;64(3):602-608. (Pubitemid 17020931)
30. Starke AAR, Erhardt G, Berger M, Zimmermann H. Elevated pancreatic glucagon in obesity. Diabetes. 1984;33:277-280. (Pubitemid 14196219)